Lead Sponsor

Federation Francophone de Cancerologie Digestive

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Metastatic disease
•At least one mesurable lesion according to RECIST V1.1 criteria
•No prior chemotherapy (excepted if there is at least on lestion out of the irradition area)
•Age \> 18 years. A favorable adviced by an onco geriatrician would be mandatory for inclusion of patients older than 75 older
•Performance statut (WHO) 0-1
•Polynyclear ≥ 1500/mm3
•Bilirubine ≤ 1,5 fois la LSN, creatinin \< 120μmol / L
•Signed informed consent form

•Another type of pancreas tumor, as endocrine tumor ou with acinous cells
•Ampulloma
•Cerebral or meningeal metastasis
•Gilbert disease
•Neuropathie \> or = grade 1
•Study treatments contraindication
•Uncontrolled diarrhoea or inflamatory disease of colon or rectum, or bowel obstruction or bowel sub-obstruction no resolved with specific treatment
•Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease prevent patient to receive study Cancer within the 5 years before inclusion, except for int situ cancer of the neck of the uterus or basal cell skin cancer
•Significant previous cardiac and respiratory disease
•Patient included in an other therapeutic study with experimental treatment
•Pregnancy or breast feeding
•Patient depreved of freedom or under gardianship
•Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Related studies

NCT07409272 · Pancreatic Cancer, Metastatic Pancreatic Cancer, and more

NCT05065801 · Metastatic Pancreatic Cancer

NCT04605913 · Pancreas Cancer, Metastatic Pancreatic Cancer, and more

NCT06662006 · Advanced Metastatic Pancreatic Cancer

NCT06861088 · Venous Thromboembolism, Metastatic Pancreatic Cancer, and more

First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem